SCHEMBL6772013

SCHEMBL6772013

CCOc1ccc(NC(=O)c2cn(C)c3c2C(=O)CCC3)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 8/20 0.49
NPC1 O15118 7/20 0.49
RAB9A P51151 7/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 5/20 0.49
MAPK1 P28482 2/20 0.49
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ABCB1 P08183 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.48
GAA P10253 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7368988 0.88 MAPT (0.48) LMNAHPGDHSD17B10TSHRMAPT
SCHEMBL6092982 0.78 TRPV1 (0.41) MAPTRAB9ATP53MAPK1KMT2A
SCHEMBL7392174 0.77 TP53 (0.52) LMNAHSD17B10MAPTNPC1RAB9A
SCHEMBL7363009 0.75 TP53 (0.55) LMNAHSD17B10MAPTNPC1RAB9A
SCHEMBL7360974 0.73 TP53 (0.48) LMNAHPGDHSD17B10MAPTNPC1
SCHEMBL7397886 0.72 NPC1 (0.54) LMNAHPGDHSD17B10MAPTNPC1
SCHEMBL7399239 0.71 TP53 (0.48) LMNAHPGDHSD17B10MAPTNPC1
SCHEMBL7400121 0.71 TAS1R3 (0.49) LMNAHPGDHSD17B10MAPTNPC1
SCHEMBL2736969 0.69 CNR2 (0.67) LMNAHPGDHSD17B10TSHRMAPT
SCHEMBL6092586 0.68 HRH3 (0.50) LMNATSHRMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6720339-B2 SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT NEUROGEN CORPORATION 2004-04-13 US disclosed
US-20020198204-A1 Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198204-A1 Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement CNR1, HTR1A, GABRA6 LMNA 2335/4885HPGD 1116/4885HSD17B10 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.